🇺🇸 Herpes Zoster in United States
14 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 14
Most-reported reactions
- Herpes Zoster — 3 reports (21.43%)
- Headache — 2 reports (14.29%)
- Pain — 2 reports (14.29%)
- Adenovirus Infection — 1 report (7.14%)
- Anaemia Haemolytic Autoimmune — 1 report (7.14%)
- Application Site Pain — 1 report (7.14%)
- Arthralgia — 1 report (7.14%)
- Back Pain — 1 report (7.14%)
- Blood Pressure Increased — 1 report (7.14%)
- Blood Urine Present — 1 report (7.14%)
Other Immunology / Infectious Disease approved in United States
Frequently asked questions
Is Herpes Zoster approved in United States?
Herpes Zoster does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Herpes Zoster in United States?
Canadian Immunization Research Network is the originator. The local marketing authorisation holder may differ — check the official source linked above.